Publications
Sakafu LL, Philipo GS, Malichewe CV, Fundikira LS, Lwakatare FA, Van Loon K, Mushi BP, DeBoer RJ, Bialous SA, Lee AY. Delayed diagnostic evaluation of symptomatic breast cancer in sub-Saharan Africa: A qualitative study of Tanzanian women. PloS one. 2022. PMID: 36201503
Kim JW, Luck C, Wu W, Ponce RK, Lin YK, Gupta N, Okimoto RA. Capicua suppresses YAP1 to limit tumorigenesis and maintain drug sensitivity in human cancer. Cell reports. 2022. PMID: 36198276
Ossowski S, Neeman E, Borden C, Stram D, Giraldo L, Kotak D, Thomas S, Suga JM, Lin A, Liu R. Improving Time to Molecular Testing Results in Patients With Newly Diagnosed, Metastatic Non-Small-Cell Lung Cancer. JCO oncology practice. 2022. PMID: 36191286
Sanft T, Day A, Peterson L, Rodriguez MA, Ansbaugh S, Armenian S, Baker KS, Ballinger T, Broderick G, Demark-Wahnefried W, Dickinson K, Fairman NP, Friedman DL, Goldman M, Henry NL, Hill-Kayser C, Hudson M, Khakpour N, Koura D, McDonough AL, Melisko M, Mooney K, Moore HCF, Moryl N, Neuman H, O'Connor T, Overholser L, Paskett ED, Patel C, Pirl W, Porpiglia A, Ruddy KJ, Schapira L, Shockney L, Smith S, Syrjala KL, Tevaarwerk A, Yang EH, Zee P, McMillian NR, Freedman-Cass DA. NCCN Guidelines� Insights: Survivorship, Version 1.2022. Journal of the National Comprehensive Cancer Network : JNCCN. 2022. PMID: 36240847
Benson AB, Venook AP, Al-Hawary MM, Azad N, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Gunn A, Hecht JR, Hoffe S, Hubbard J, Hunt S, Jeck W, Johung KL, Kirilcuk N, Krishnamurthi S, Maratt JK, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stotsky-Himelfarb E, Tavakkoli A, Willett CG, Gregory K, Gurski L. Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2022. PMID: 36240850
Kelley RK. The Evolving Role of Combination Systemic Therapies in Hepatocellular Carcinoma. Gastroenterology & hepatology. 2022. PMID: 36397929
Tempero M. We Are Winning This War! Journal of the National Comprehensive Cancer Network : JNCCN. 2022. PMID: 36240853
Rubenstein JL. Primary CNS Lymphoma: Progress With Dose-Intensive Consolidation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022. PMID: 36179277
Christina Phuong, Amy M. Lin, Izzy Friesner, Lisa Ni, Rahul Raj Aggarwal, Hala Borno, Vadim S Koshkin, Arpita Desai, Terence W. Friedlander, Lawrence Fong, Rohit Bose, Jonathan Chou, Tammy J. Rodvelt, Osama Mohamad, Anthony C. Wong, Felix Y Feng, Eric Jay Small, Julian C. Hong. Reliability of real-world data for diagnosis of metastatic prostate cancer. Journal of Clinical Oncology. 2022. PMID:
Allen GM, Lim WA. Rethinking cancer targeting strategies in the era of smart cell therapeutics. Nature reviews. Cancer. 2022. PMID: 36175644
Schoeps VA, Graves JS, Stern WA, Zhang L, Nourbakhsh B, Mowry EM, Henry RG, Waubant E. N-Acetyl Cysteine as a Neuroprotective Agent in Progressive Multiple Sclerosis (NACPMS) trial: Study protocol for a randomized, double-blind, placebo-controlled add-on phase 2 trial. Contemporary clinical trials. 2022. PMID: 36182028
Aggarwal R, Alumkal JJ, Szmulewitz RZ, Higano CS, Bryce AH, Lopez-Gitlitz A, McCarthy SA, Miladinovic B, McQuarrie K, Thomas S, Zhang K, Small EJ. Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer. Prostate cancer. 2022. PMID: 36212187
Ailawadhi S, Ogbonnaya A, Murty S, Cherepanov D, Schroader BK, Romanus D, Farrelly E, Chari A. Duration of frontline therapy and impact on clinical outcomes in newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant. Cancer medicine. 2022. PMID: 36151787
Smith JL, Menzies AM, Cohen JV, Mut-Lloret M, Ozgun A, Spain L, Park J, Quach HT, Pallan L, McQuade J, Feng S, Sandhu S, Atkinson V, Tsai K, Long GV, Larkin J, Eroglu Z, Johnson DB, Sullivan R, Herkes GK, Henderson A, Carlino MS. Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series. Melanoma research. 2022. PMID: 36164923
Spanogiannopoulos P, Kyaw TS, Guthrie BGH, Bradley PH, Lee JV, Melamed J, Malig YNA, Lam KN, Gempis D, Sandy M, Kidder W, Van Blarigan EL, Atreya CE, Venook A, Gerona RR, Goga A, Pollard KS, Turnbaugh PJ. Host and gut bacteria share metabolic pathways for anti-cancer drug metabolism. Nature microbiology. 2022. PMID: 36138165
Goel S, Tan AR, Rugo HS, Aftimos P, Andric Z, Beelen A, Zhang J, Yi JS, Malik R, O'Shaughnessy J. Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2. Future oncology (London, England). 2022. PMID: 36135712
Bennett NK, Nakaoka HJ, Laurent D, Okimoto RA, Sei Y, Horvai AE, Bivona TG, Ten Hoeve J, Graeber TG, Nakamura K, Nakamura JL. Primary and metastatic tumors exhibit systems-level differences in dependence on mitochondrial respiratory function. PLoS biology. 2022. PMID: 36137002
Fillbrunn M, Signorovitch J, Andr? F, Wang I, Lorenzo I, Ridolfi A, Park J, Dua A, Rugo HS. PIK3CA mutation status, progression and survival in advanced HR?+?/HER2- breast cancer: a meta-analysis of published clinical trials. BMC cancer. 2022. PMID: 36131248
Keenan BP, McCarthy EE, Ilano A, Yang H, Zhang L, Allaire K, Fan Z, Li T, Lee DS, Sun Y, Cheung A, Luong D, Chang H, Chen B, Marquez J, Sheldon B, Kelley RK, Ye CJ, Fong L. Circulating monocytes associated with anti-PD-1 resistance in human biliary cancer induce T cell paralysis. Cell reports. 2022. PMID: 36130508
Martin T, Jackson CC, Pacaud L, Madduri D, Jagannath S. Recent Advances in the Use of Chimeric Antigen Receptor-Expressing T-Cell Therapies for Treatment of Multiple Myeloma. Clinical lymphoma, myeloma & leukemia. 2022. PMID: 36411210